JAGSNPHARM Jagsonpal Pharmaceuticals Q1 FY27 results (Apr–Jun 2026) and concall
Jagsonpal Pharmaceuticals delivered a strong Q1 FY27, with robust revenue and profit growth driven by strategic portfolio shifts and operational efficiencies. The quarter also marked the significant acquisition of Aequitas Healthcare, signaling a strategic entry into the hospital segment with ambitious growth targets. While some discrepancies in sales growth and Aequitas's margin profile were noted, management provided clear strategic rationales and plans for integration and improvement.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 7.9%, net profit up 18.2% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 75 | 74 | 59 | 76 | 74 −1% | 73 −1% | 64 +8% | 82 +8% |
| EBITDA | 16 | 16 | 9 | 14 | 16 +0% | 16 +0% | 11 +22% | 17 +21% |
| Net profit | 11 | 32 | 7 | 11 | 13 +18% | 11 −66% | 9 +29% | 13 +18% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
